Hiroki Kobayashi, Yoshiaki Abe, Daisuke Miura, Kentaro Narita, Akihiro Kitadate, Masami Takeuchi, Kosei Matsue (Hematology, Kameda Medical Center, Chiba, Japan)
Session information
Oral Session
Oral Session 1-10A MM: Prognosis
Fri. Oct 12, 2018 9:00 AM - 10:00 AM No.10 (Osaka International Convention Center, 10F 1009)
Chair: Hiromi Iwasaki (National Hospital Organization Kyusyu Medical Center, Japan)
Tetsuya Kobayashi, Yoshiaki Abe, Kentaro Narita, Hiroki Kobayashi, Akihiro Kitadate, Masami Takeuchi, Kosei Matsue (Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center)
Hiroki Kobayashi, Yoshiaki Abe, Daisuke Miura, Kentaro Narita, Akihiro Kitadate, Masami Takeuchi, Kosei Matsue (Hematology, Kameda Medical Center, Chiba, Japan)
Yoshiaki Abe, Kentaro Narita, Hiroki Kobayashi, Akihiro Kitadate, Masami Takeuchi, Kosei Matsue (Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center)
Hirokazu Tanaka1,22, Kentaro Serizawa1,23, Aya Nakaya2,23, Hitomi Kaneko3,23, Kensuke Ohta4,23, Satoru Kosugi5,23, Hideo Yagi6,23, Hitoshi Hanamoto7,23, Shin-Ichi Fuchida8,23, Yuji Shimura9,23, Hirohiko Shibayama10,23, Takae Kohara10,23, Eiji Nakatani11,23, Junya Kanda12,23, Nobuhiko Uoshima13,23, Katsuya Wada14,23, Takahiro Karasuno15,23, Toshimitsu Matsui16,23, Hitoji Uchiyama17,23, Mitsuhiro Matsuda18,23, Yoko Adachi19,23, Akifumi Takaori-Kondo12,23, Junya Kuroda9,23, Masafumi Taniwaki20,23, Chihiro Shimazaki8,23, Masayuki Hino21,23, Kazunori Imada3,23, Shosaku Nomura22,23, Yuzuru Kanakura10,23, Itaru Matsumura1,23 (1.Hematolog and Rheumatology, Kindai University, Osaka, Japan, 2.Hematology and Oncology, Kansai Medical University Medical Center, Osaka, Japan, 3.Hematology, Osaka Red Cross Hospital, Osaka, Japan, 4.Hematology, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan, 5.Internal Medicine (Hematology), Toyonaka Municipal Hospital, Osaka, Japan, 6.Hematology and Oncology, Nara Prefecture General Medical Center, Nara, Japan, 7.Hematology, Kindai University Nara Hospital, Nara, Japan, 8.Hematology, JCHO Kyoto Kuramaguchi Medical Center, Kyoto, Japan, 9.Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan, 10.Hematology and Oncology, Osaka University, Osaka, Japan, 11.Biostatistics and Data Science, Osaka University, Osaka, Japan, 12.Hematology and Oncology, Kyoto University, Kyoto, Japan, 13.Hematology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan, 14.Hematology, Matsushita Memorial Hospital, Osaka, Japan, 15.Hematology, Rinku General Medical Center, Osaka, Japan, 16.Hematology, Nishiwaki Municipal Hospital, Hyogo, Japan, 17.Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan, 18.Hematology, PL General Hospital, Osaka, Japan, 19.Hematology, Kobe Central Hospital, Hyogo, Japan, 20.Molecular Diagnostics Therapeutics, Kyoto Prefectural University of Medicine, Kyoto, Japan, 21.Hematology, Osaka City University, Osaka, Japan, 22.First Department of Internal Medicine, Kansai Medical University, Osaka, Japan, 23.Kansai Myeloma Forum, Osaka, Japan)
Takaaki Cho1, Shuusaku Matsuda2, Izumi Mishiro2, Junpei Soeda2, Kenshi Suzuki3 (1.Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan, 2.Japan Medical Affairs, Takeda Pharmaceuticals Company Limited, Tokyo, Japan, 3.Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan)